Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560624 | 0.84 | BCHE (0.51) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL6489268 | 0.82 | BCHE (0.40) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL14921756 | 0.76 | AR (0.33) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL4363073 | 0.76 | BCHE (0.33) | BCHEMAPTNPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3638684 | 0.75 | KDM4E (0.49) | NPC1RAB9AMAPTKDM4EKMT2A | |
| SCHEMBL4623912 | 0.75 | METAP2 (0.35) | NPC1MAPTKDM4EL3MBTL1KMT2A | |
| SCHEMBL29986041 | 0.75 | BCHE (0.58) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL158912 | 0.75 | BCHE (0.58) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL5622080 | 0.74 | AR (0.36) | BCHENPC1RAB9AMAPTKDM4E | |
| SCHEMBL7077778 | 0.74 | MAPT (0.50) | BCHENPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005392-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI (FR) | 2014-01-02 | — | — | US | claimed |
| EP-1670766-B1 | Bicyclic imino acid derivatives for the treatment of (inter alia) diseases relating to the locomotor system | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-03-21 | — | — | EP | claimed |
| JP-4733642-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| JP-4676960-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| JP-4658940-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-7910576-B2 | Pyrrole derivatives as P2Y12 antagonists | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | claimed |
| US-20110039829-A1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | claimed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | claimed |
| US-20070155778-A1 | 4-Trifluoromethoxyphenoxybenzol-4-Sulfonic Acids, Method For The Production And Use Thereof In Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-05 | — | — | US | claimed |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-09 | — | — | US | claimed |
| US-20050080127-A1 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-14 | — | — | US | claimed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | claimed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | claimed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | BCHE 2364/4885NPC1 3963/4885RAB9A 1159/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | BCHE 1097/4885NPC1 4215/4885RAB9A 3260/4885 |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | BCHE 1122/4885NPC1 4571/4885RAB9A 3066/4885 |
| US-20050080127-A1 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP17, MMP25 | BCHE 804/4885NPC1 1079/4885RAB9A 2905/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | BCHE 3348/4885NPC1 4195/4885RAB9A 1273/4885 |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | TPH2, IDO2, IDO1 | BCHE 1398/4885NPC1 4430/4885RAB9A 2076/4885 |
| US-20140005392-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | TPH2, IDO2, IDO1 | BCHE 1882/4885NPC1 4223/4885RAB9A 1827/4885 |
| US-20110039829-A1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | BCHE 3234/4885NPC1 4213/4885RAB9A 1375/4885 |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SULT2A1, ADCYAP1R1, SULT1A1 | BCHE 1172/4885NPC1 1054/4885RAB9A 2119/4885 |
| US-20070155778-A1 | 4-Trifluoromethoxyphenoxybenzol-4-Sulfonic Acids, Method For The Production And Use Thereof In Medicaments | CYP4X1, AFF1, BPGM | BCHE 2787/4885NPC1 1445/4885RAB9A 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.